A pediatric B lineage leukemia with coincident MYC and MLL translocations

J Pediatr Hematol Oncol. 2011 Mar;33(2):158-60. doi: 10.1097/MPH.0b013e3181e65c39.

Abstract

Translocations are key oncogenic events, and many rearrangements are characteristic for a specific malignancy. We present here a case of phenotypic precursor-B acute lymphoblastic leukemia (ALL), subsequently found to have both MYC and MLL translocations. Owing to the potential prognostic impact of these translocations, a novel treatment strategy was applied which merged precursor-B ALL, Burkitt-ALL, and "MLL-adapted" rationales. With the advent of expanding diagnostic panels and molecular therapeutic options, use of such adapted therapies for individualized treatment will undoubtedly continue to increase as we move toward pharmacogenomic-based approaches.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Child, Preschool
  • Cyclophosphamide / administration & dosage
  • Cytarabine / administration & dosage
  • Doxorubicin / administration & dosage
  • Flow Cytometry
  • Histone-Lysine N-Methyltransferase
  • Humans
  • Male
  • Methotrexate / administration & dosage
  • Myeloid-Lymphoid Leukemia Protein / genetics*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Prednisone / administration & dosage
  • Proto-Oncogene Proteins c-myc / genetics*
  • Translocation, Genetic*
  • Vincristine / administration & dosage

Substances

  • KMT2A protein, human
  • MYC protein, human
  • Proto-Oncogene Proteins c-myc
  • Cytarabine
  • Myeloid-Lymphoid Leukemia Protein
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Histone-Lysine N-Methyltransferase
  • Prednisone
  • Methotrexate